UBS Upgrades Jazz Pharmaceuticals to Buy, Sets $307 Target
UBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
Glide path describes how a target date fund changes its asset mix as the target year approaches, balancing risk and growth for your retirement.
25,488 articlesUBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
A respected analyst has earmarked Dutch Bros as the best restaurant stock pick, citing traffic gains, digital momentu...
Investors pursue a $5,000‑a‑month after‑tax dividend target to resemble a mid‑career Indiana police officer’s take‑ho...
When a global pharma giant drops $1 billion on a single tech, investors sit up. This move by Johnson Johnson Just Pai...
A wave of new analyst ratings hits screens Friday, touching auto parts, semiconductors, software and biotech. Upgrade...
Ready to turn a five-year vision into reality? Learn a proven path to five short-term rentals five, from financing to...
UBS boosts its price target on Xcel Energy to $89 while maintaining a Buy rating, saying the stock could year-end hig...
UBS cuts Mosaic’s price target to $27, citing squeezed phosphate margins from higher sulfur and input costs, as Wall ...
AMD is grabbing attention as its stock soars. This guide breaks down the core drivers, the risks, and concrete steps ...
The market feels pricey, but bargains hide in plain sight. Here are three deeply undervalued stocks less than $100, p...
As March kicks off, many investors look for a starting point in energy. Here's first energy stock could fit a growth-...
As year-to-date markets swing, Disney and PayPal stand out as potential rebound plays. This article weighs dividends,...